Advanced Medical Solutions Group (AMS) H2 2025 earnings summary

Executive summary

• 2025 strategic objectives achieved, with group revenue doubling over four years and a 29% increase in 2025 alone.

• Portfolio expansion, geographic growth, and successful integration of acquired businesses underpin performance.

• Strong pipeline of new products and commercial synergies expected to sustain long-term growth.

Financial highlights

• Group revenue rose 29% year-over-year to £228.9 million; revenue has doubled since 2021.

• Adjusted EBITDA increased 24% to £49.9 million; adjusted pre-tax profit up 15% to £33.9 million.

• Adjusted EPS grew 12% to 11.74p; net debt reduced to £50.5 million from £55.8 million.

• Proposed 10% increase in full-year dividend to 2.86p per share, marking five consecutive years of double-digit dividend growth.

Outlook and guidance

• Performance for 2026 expected to align with current market expectations.

• Continued strong growth anticipated, driven by surgical business, geographic expansion, and new product approvals.

• Operational synergies and inventory unwind expected to significantly improve margins and cash flow from 2027.